Advanced Search

 

Study ID Status Title Patient Level Data
113074 Completed Value of Early 5-alpha-reductase Inhibitor (5ARI) Treatment in Patients Receiving Combination 5ARI and Alpha-Blocker (AB) Therapy for Enlarged Prostate (EP)
113077 Completed Efficacy, safety and immunogenicity study of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A in adults aged 70 years or older
113078 Active not recruiting A Study to Evaluate Efficacy and Safety of Pazopanib versus Sunitinib for the Treatment of Asian Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma – A substudy to VEG108844
113079 Terminated Clinical evaluation of ropinirole IR (immediate release) tablets in patients who are diagnosed with symptomatic restless legs syndrome (RLS) associated with Chronic kidney disease (CKD) managed with haemodialysis (including haemofiltration and haemodiafiltration) Study Listed on ClinicalStudyDataRequest.com
113086 Active not recruiting A randomized, double blind study of the safety and efficacy of GSK1349572 50mg once daily to raltegravir 400mg twice daily both administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral therapy naive adult subjects
113090 Completed A randomised, double-blind, placebo-controlled, three-way crossover, repeat dose pilot study comparing the effect of inhaled fluticasone furoate/GW642444M combination and fluticasone furoate on the allergen-induced early asthmatic response in subjects with mild asthma Study Listed on ClinicalStudyDataRequest.com
113091 Completed A randomised, double-blind, double-dummy, parallel-group multicentre study to assess efficacy and safety of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Propionate/Salmeterol Inhalation Powder in the treatment of persistent asthma in adults and adolescents Study Listed on ClinicalStudyDataRequest.com
113092 Active not recruiting Drug Use Investigation for TYKERB tablet (All case investigation)
113094 Completed Observer-blind safety and immunogenicity study of GlaxoSmithKline Biologicals’ influenza vaccine GSK2186877A when administered to elderly subjects Study Listed on ClinicalStudyDataRequest.com
113095 Completed Special Drug Use Investigation for ADOAIR DISKUS COPD (salmeterol and fluticasone)
113095 Completed Special Drug Use Investigation for ADOAIR DISKUS COPD (salmeterol and fluticasone)
113096 Completed An Open-Label, Single Sequence, Three-Period Drug Interaction Study of GSK1349572 and Tipranavir/Ritonavir in Healthy Adult Subjects (ING113096)
113097 Completed A Phase I, Open-Label, Parallel-Group, Two-Part, Adaptive Study to Evaluate the Pharmacokinetics and Safety of GSK1349572 in Subjects with Hepatic Impairment and Healthy Matched Control Subjects (ING113097)
113099 Completed Phase 1, open label, two arm, fixed sequence study to evaluate the effect of rifampin and rifabutin on GSK1349572 pharmacokinetics in healthy male and female volunteers
113100 Completed A Pilot dose-finding and pharmacokinetic study of fondaparinux in children with deep vein thrombosis or heparin-induced thrombocytopenia
113101 Withdrawn A Phase IV study evaluating eltrombopag concentrations in breast milk of nursing mothers taking eltrombopag
113107 Completed A 12-week study to evaluate the 24 hour pulmonary function of Fluticasone Furoate (FF)/Vilanterol Inhalation Powder (FF/VI Inhalation Powder) once daily compared with Salmeterol/Fluticasone Propionate (FP) Inhalation Powder twice daily in subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
113108 Completed A 24-week study to evaluate the effect of fluticasone furoate/vilanterol 100/25 mcg Inhalation Powder delivered once-daily via a Novel Dry Powder Inhaler on arterial stiffness compared with placebo and vilanterol in subjects with Chronic Obstructive Pulmonary Disease (COPD). Study Listed on ClinicalStudyDataRequest.com
113109 Completed A 12-week Study to Evaluate the 24-hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg once daily Compared with Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg twice daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
113120 Completed Safety, tolerability, pharmacokinetics and pharmacodynamics of the combination of GSK573719 and GW642444 in subjects with COPD Study Listed on ClinicalStudyDataRequest.com
113121 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects with Type 2 Diabetes Mellitus Study Listed on ClinicalStudyDataRequest.com
113124 Completed An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects with Ovarian Cancer
113125 Completed A Phase I, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetics and Safety of Dolutegravir in Subjects with Renal Impairment and Healthy Matched Control Subjects (ING113125)
113126 Completed A randomised, double-blind, placebo-controlled, four-way crossover, repeat dose study comparing the effect of inhaled fluticasone furoate/GW642444M combination, GW642444M and fluticasone furoate on the allergen-induced asthmatic response in subjects with mild asthma Study Listed on ClinicalStudyDataRequest.com
113132 Completed A study in type 2 diabetic subjects on stable metformin therapy to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of co-administering single and multiple oral doses of GSK1292263 Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.